Results 171 to 180 of about 136,303 (402)

Pulmonary congestion relief by adding dapagliflozin to intravenous loop diuretic in acute heart failure patients

open access: yesESC Heart Failure, EarlyView.
Abstract Aims We aim to assess the efficacy of congestion relief and safety associated with adding SGLT2i (viz., dapagliflozin 10 mg) to intravenous loop diuretics within 24 h of hospital presentation in patients with acute heart failure (AHF). Methods and results A single‐centre open‐label clinical research study enrolled 98 patients admitted with an ...
Daniela Mocan   +7 more
wiley   +1 more source

Atrial Natriuretic Factor (ANF) Inhibits Ca-Dependent K-Fluxes in Cultured Vascular Smooth Muscle Cells

open access: bronze, 1986
Ricardo P. Garay   +9 more
openalex   +1 more source

Angiotensin receptor‐neprilysin inhibitors in concurrent heart failure with reduced ejection fraction and kidney failure

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Angiotensin receptor‐neprilysin inhibitor (ARNI) therapy has demonstrated improved outcomes in heart failure with reduced ejection fraction (HFrEF). However, its benefits in patients with concomitant kidney failure undergoing replacement therapy remain uncertain. Methods and results Using the National Health Insurance Service database, we
Mi‐Hyang Jung   +8 more
wiley   +1 more source

Antihypertensive and hypotensive effects of atrial natriuretic factor in men. [PDF]

open access: bronze, 1987
A Weder   +4 more
openalex   +1 more source

Atrial cardiomyopathy

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala   +1 more
wiley   +1 more source

Immuno‐haemostatic dysregulation in heart failure with preserved ejection fraction

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) is a complex condition with partially unclear pathophysiology, in which systemic inflammation is a central contributor to changes in cardiac structure and function. The contribution of non‐traditional immune effectors—such as platelets and coagulation—remains underexplored in HFpEF ...
Giorgia D'Italia   +13 more
wiley   +1 more source

Clinical endpoints in pragmatic heart failure trials: From data collection to clinical endpoint classification

open access: yesESC Heart Failure, EarlyView.
Abstract Clinical endpoint classification (CEC)—that is, evaluation of clinical events using pre‐defined criteria—is commonly conducted in clinical trial operations to ensure systematic and consistent assessment of endpoints needed to assess the intervention's safety and efficacy.
Veraprapas Kittipibul   +13 more
wiley   +1 more source

Plasma Levels of Atrial Natriuretic Factor in Patients with Cardiac Arrhythmias and Congestive Heart Failure

open access: bronze, 1986
Hidenori Nakaoka   +6 more
openalex   +1 more source

A comparison of synthetic rat and human atrial natriuretic factor in conscious dogs. [PDF]

open access: bronze, 1986
Andrea A. Seymour   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy